Recombinant Plasmid miRNA Control of Immune Checkpoint Expression

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Bioactive molecules, such as immune checkpoint molecules, when overexpressed or misexpressed, disrupt homeostasis leading to disease, necessitating therapies to regulate their production.

Innovation Solution

Compositions comprising recombinant plasmids that encode miRNA sequences targeting the mRNA of immune checkpoint molecules like PD-1, PD-L1, PD-L2, CTLA4, or IDO1, administered to upregulate miRNA production, thereby decreasing the translation or production of these molecules.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If immune checkpoint molecules are overexpressed to enhance immune response, then anti-tumor activity is improved, but homeostasis is disrupted and disease occurs

Engineering Contradiction:
Improveimmune response effectivenessVSAvoidhomeostasis
Core Design Contradiction:
ReliabilityVSStability of the object's composition

Solution Approach 1:

The patent introduces miRNA sequences that provide negative feedback regulation on immune checkpoint molecules. The miRNAs bind to mRNA of checkpoint molecules (PD-1, PD-L1, PD-L2, CTLA4, IDO1) and degrade them, creating a feedback loop that restores homeostasis when checkpoint molecules are overexpressed, thereby treating the disease while maintaining immune response effectiveness

Inventive Principle:
Principle #23Feedback

Solution Approach 2:

The patent changes the expression level parameter of immune checkpoint molecules from overexpressed to controlled levels. By introducing miRNA compositions that degrade checkpoint molecule mRNA, the invention adjusts the concentration parameter of these molecules back to physiological ranges, restoring homeostasis without compromising immune function

Inventive Principle:
Principle #35Parameter changes

2Stability of the object's composition

If checkpoint molecules are downregulated to restore homeostasis, then disease is treated, but immune response may be compromised

Engineering Contradiction:
ImprovehomeostasisVSAvoidimmune response effectiveness
Core Design Contradiction:
Stability of the object's compositionVSReliability

Solution Approach 1:

The patent employs endogenous miRNA sequences that are naturally produced by the host's immune system. These miRNAs self-regulate checkpoint molecule expression without requiring external intervention, allowing the immune system to restore homeostasis autonomously while maintaining appropriate immune response levels through its own regulatory mechanisms

Inventive Principle:
Principle #25Self-service

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The compositions effectively downregulate immune checkpoint molecules, restoring homeostasis and potentially treating associated diseases by increasing miRNA production to degrade or inactivate their mRNA.

Implementation Method 1

the miRNA can cause the target mRNA to be degraded or inactivated, thereby causing a decrease in bioavailability of the target biomolecule

Methodology Applied
Scientific EffectRNA interference:

Data Source

PatentUS12618075B2Composition for regulating production of interfering ribonucleic acid
Publication Date: 2026.05.05 WYVERN PHARMACEUTICALS INC

AI summary

Embodiments of the present disclosure relate to a composition that comprises a recombinant plasmid (RP) with a sequence of nucleic acids. The sequence comprise a start region, an end region and an insert positioned between the start region and the end region. The insert encodes for a sequence of micro interfering ribonucleic acid (miRNA) that may be complementary to a sequence of target messenger RNA (mRNA) that encodes for translation of a target biomolecule. The miRNA can cause the target mRNA to be degraded or inactivated, thereby causing a decrease in bioavailability of the target biomolecule because it is degraded or inactivated by the miRNA, thereby decreasing the bioavailability of the target biomolecule. In some embodiments of the present disclosure, the target biomolecule is an immune checkpoint protein.